Form 4: Immunovant CFO Sells Shares to Cover Tax Obligations

Eva Renee Barnett, CFO of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On April 17, 2024, Eva Renee Barnett, the Chief Financial Officer of Immunovant, Inc., sold 9,479 shares of common stock at a weighted average price of $28.8.
• She also sold 2,774 shares of common stock at a weighted average price of $29.94.
• These sales were to cover tax withholding obligations related to the vesting of 21,916 restricted stock units (RSUs) on April 12, 2024.
• The sales were mandated by Immunovant's policy requiring tax obligations to be funded by a 'sell to cover' transaction.
• Following these transactions, Barnett directly owns 359,456 shares of Immunovant common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. It doesn't indicate any significant positive or negative developments for the company.

Positives

• The 'sell to cover' policy ensures tax obligations are met without requiring the executive to use personal funds.

Industry Context

Executive stock sales are a common occurrence, particularly when tied to vesting events of equity compensation. The 'sell to cover' mechanism is a standard practice to manage tax obligations.

Comparison to Industry Standards

• The 'sell to cover' practice is widely used across the biotechnology and pharmaceutical industries, including companies like Amgen, Regeneron, and Gilead Sciences, to facilitate tax payments on vested equity awards.
• The weighted average prices of $28.8 and $29.94 per share are within a normal range for stock transactions related to tax obligations.

Stakeholder Impact

• The transaction has a minimal impact on shareholders, as it is a routine sale to cover tax obligations.

Key Dates